These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
134 related articles for article (PubMed ID: 33061437)
21. SHOX2 is a Potent Independent Biomarker to Predict Survival of WHO Grade II-III Diffuse Gliomas. Zhang YA; Zhou Y; Luo X; Song K; Ma X; Sathe A; Girard L; Xiao G; Gazdar AF EBioMedicine; 2016 Nov; 13():80-89. PubMed ID: 27840009 [TBL] [Abstract][Full Text] [Related]
22. Analysis of IDH mutation, 1p/19q deletion, and PTEN loss delineates prognosis in clinical low-grade diffuse gliomas. Sabha N; Knobbe CB; Maganti M; Al Omar S; Bernstein M; Cairns R; Çako B; von Deimling A; Capper D; Mak TW; Kiehl TR; Carvalho P; Garrett E; Perry A; Zadeh G; Guha A; Sidney Croul Neuro Oncol; 2014 Jul; 16(7):914-23. PubMed ID: 24470545 [TBL] [Abstract][Full Text] [Related]
23. Impact of 1p/19q codeletion status on extent of resection in WHO grade II glioma: Insights from a national cancer registry. Lu VM; Alvi MA; Bydon M; Quinones-Hinojosa A; Chaichana KL Clin Neurol Neurosurg; 2019 Jul; 182():32-36. PubMed ID: 31063969 [TBL] [Abstract][Full Text] [Related]
24. The T2-FLAIR-mismatch sign as an imaging biomarker for IDH and 1p/19q status in diffuse low-grade gliomas: a systematic review with a Bayesian approach to evaluation of diagnostic test performance. Goyal A; Yolcu YU; Goyal A; Kerezoudis P; Brown DA; Graffeo CS; Goncalves S; Burns TC; Parney IF Neurosurg Focus; 2019 Dec; 47(6):E13. PubMed ID: 31786548 [TBL] [Abstract][Full Text] [Related]
25. Molecular profiles for insular low-grade gliomas with putamen involvement. Zhou C; Wang Y; Liu X; Liang Y; Fan Z; Jiang T; Wang Y; Wang L J Neurooncol; 2018 Jul; 138(3):659-666. PubMed ID: 29556911 [TBL] [Abstract][Full Text] [Related]
26. Comparative Analysis of Brain Coping Mechanisms in Small Left-Hemisphere Lesions: Incidental vs. Symptomatic Gliomas. Cargnelutti E; Ius T; Maieron M; D'Agostini S; Skrap M; Tomasino B Brain Sci; 2024 Aug; 14(9):. PubMed ID: 39335382 [TBL] [Abstract][Full Text] [Related]
28. Zhao K; Yu P; Xue Z; Liu J; Yao A; Zhao Y; Yang F; Tian J; Xu B Acad Radiol; 2020 Jul; 27(7):e159-e167. PubMed ID: 31607471 [TBL] [Abstract][Full Text] [Related]
29. Non-invasive genotype prediction of chromosome 1p/19q co-deletion by development and validation of an MRI-based radiomics signature in lower-grade gliomas. Han Y; Xie Z; Zang Y; Zhang S; Gu D; Zhou M; Gevaert O; Wei J; Li C; Chen H; Du J; Liu Z; Dong D; Tian J; Zhou D J Neurooncol; 2018 Nov; 140(2):297-306. PubMed ID: 30097822 [TBL] [Abstract][Full Text] [Related]
30. The prognostic value of clinical factors and cancer stem cell-related markers in gliomas. Dahlrot RH Dan Med J; 2014 Oct; 61(10):B4944. PubMed ID: 25283629 [TBL] [Abstract][Full Text] [Related]
32. Improved survival in the largest national cohort of adults with cerebellar versus supratentorial low-grade astrocytomas. Bagley JH; Babu R; Friedman AH; Adamson C Neurosurg Focus; 2013 Feb; 34(2):E7. PubMed ID: 23373452 [TBL] [Abstract][Full Text] [Related]
33. Normal-appearing white matter structural integrity in incidentally discovered low-grade gliomas: a single institution study. Cargnelutti E; Maieron M; Ius T; Skrap M; Tomasino B J Neurosurg Sci; 2023 Apr; 67(2):200-205. PubMed ID: 33245224 [TBL] [Abstract][Full Text] [Related]
34. The Diagnostic Value of Conventional MRI and CT Features in the Identification of the IDH1-Mutant and 1p/19q Co-Deletion in WHO Grade II Gliomas. Zhao K; Sun G; Wang Q; Xue Z; Liu G; Xia Y; Yao A; Zhao Y; You N; Yang C; Xu B Acad Radiol; 2021 Jul; 28(7):e189-e198. PubMed ID: 32359929 [TBL] [Abstract][Full Text] [Related]
35. Introduction of a standardized multimodality image protocol for navigation-guided surgery of suspected low-grade gliomas. Mert A; Kiesel B; Wöhrer A; Martínez-Moreno M; Minchev G; Furtner J; Knosp E; Wolfsberger S; Widhalm G Neurosurg Focus; 2015 Jan; 38(1):E4. PubMed ID: 25552284 [TBL] [Abstract][Full Text] [Related]
36. Clinical relevance of 1p and 19q deletion for patients with WHO grade 2 and 3 gliomas. Iwamoto FM; Nicolardi L; Demopoulos A; Barbashina V; Salazar P; Rosenblum M; Hormigo A J Neurooncol; 2008 Jul; 88(3):293-8. PubMed ID: 18345516 [TBL] [Abstract][Full Text] [Related]
37. CHI3L2 Is a Novel Prognostic Biomarker and Correlated With Immune Infiltrates in Gliomas. Liu L; Yang Y; Duan H; He J; Sun L; Hu W; Zeng J Front Oncol; 2021; 11():611038. PubMed ID: 33937022 [TBL] [Abstract][Full Text] [Related]
38. Over-expression of lysyl oxidase is associated with poor prognosis and response to therapy of patients with lower grade gliomas. Huang SP; Chiou J; Jan YH; Lai TC; Yu YL; Hsiao M; Lin YF Biochem Biophys Res Commun; 2018 Jun; 501(3):619-627. PubMed ID: 29729273 [TBL] [Abstract][Full Text] [Related]
39. LGALS3 Is a Poor Prognostic Factor in Diffusely Infiltrating Gliomas and Is Closely Correlated With CD163+ Tumor-Associated Macrophages. Hu WM; Yang YZ; Zhang TZ; Qin CF; Li XN Front Med (Lausanne); 2020; 7():182. PubMed ID: 32528967 [No Abstract] [Full Text] [Related]